Tebentafusp (NCT06070012)

Name: Tebentafusp trial for Uveal Melanoma (NCT06070012)
Uploaded: 2026-10-31T18:04:33.572Z
Duration: 1 min 18 s
Description: Tebentafusp trial for Uveal Melanoma (NCT06070012). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06070012.

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma: a one-minute explainerNCT060700121 min

Tebentafusp trial for Uveal Melanoma (NCT06070012). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with metastatic uveal melanoma and HLA-A*0201. Prior systemic treatment for advanced disease or liver-directed treatment is excluded; prior removal of limited metastases is allowed. Fresh tumor biopsy is required.

The idea: tebentafusp links T cells to melanoma cells displaying gp100, aiming to trigger immune attack. Weekly doses rise from 20 to 30 to 68 micrograms. Researchers measure changes in circulating tumor DNA, alongside clinical assessments.

This phase 2 study plans 44 patients. UPMC’s Diwakar Davar leads it; four US sites are recruiting, including Pittsburgh.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.